Assessment of canine autologous platelet-rich plasma produced with a commercial centrifugation and platelet recovery kit

Summary

Objectives: To characterize the cellular composition (platelets, erythrocytes, and leukocytes) and confirm reproducibility of platelet enrichment, as well as determine the platelet activation status in the final product of a commercial platelet-rich plasma kit using canine blood.

Methods: Venous blood from 20 sedated client-owned dogs was used to prepare platelet-rich plasma (PRP) from a commercial kit. Complete blood counts were performed to determine erythrocyte, leukocyte, and platelet numbers in both whole blood (WB) and resultant PRP. The WB and PRP samples from jugular (fast collection) and cephalic (slow collection) venipuncture were also compared. P-selectin externalization was measured in WB and PRP samples from 15 of 20 dogs.

Results: This commercial kit produced an average percent recovery in platelets of 64.7 ± 17.4; erythrocytes of 3.7 ± 0.8, and leukocytes of 31.6 ± 10.0. Neutrophil, monocyte, and lymphocyte percent recovery was 19.6 ± 7.2, 44.89 ± 19.8, and 57.5 ± 10.6, respectively. The recovery of platelets from jugular venipuncture (59.7 ± 13.6%) was lower than from cephalic recovery (68.8 ± 19.1%). The mean percent P-Selectin externalization for WB, PRP, and PRP with thrombin was 25.5 ± 30.9, 4.5 ± 6.4, and 90.6 ± 4.4 respectively.

Clinical significance: Cellular reproducibility of this kit was confirmed and platelets were concentrated within autologous serum. Additionally, measurements of P-selectin externalization showed that platelets are inactive in PRP unless stimulated to degranulate.

Keywords

Platelet-rich plasma - PRP - P-selectin - platelet activation - leukocytes - canine

• References

• 1 Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leukocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 2009; 27: 158-167.
• 2 Eppley BL, Woodell JE, Higgens J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114: 1502-1508.
• 3 Nguyen RT, Borg-Stein J, McInnis K. Applications of platelet-rich plasma in musculoskeletal and sports medicine: an evidence-based approach. PM R 2011; 3: 226-250.
• 4 Fahie MA, Ortolano GA, Guercio V. et al. A randomized controlled trial of the efficacy of autologous platelet therapy for the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 2013; 9: 1291-1297.
• 5 Kaux JF, Forthomme B, Namurois MH. et al. Description of a standardized rehabilitation program based on sub-maximal eccentric following a platelet-rich plasma infiltration for jumper's knee. Muscles Ligaments Tendons J 2014; 4: 85-89.
• 6 Bosch G, van Schie HT, de Groot MW. et al. Effects of platelet-rich plasma on the quality of repair of mechanically induced core lesions in equine superficial digital flexor tendons: a placebo-controlled experimental study. J Orthop Res 2010; 28: 211-217.
• 7 Franklin SP, Cook JL. Prospective trial of autologous conditioned plasma versus hyaluronan plus corticosteroid for elbow osteoarthritis in dogs. Can Vet J 2013; 54: 881-884.
• 8 Murray MM, Spindler KP, Devin C. et al. Use of collagen-platelet rich plasma scaffold to stimulate healing of a central defect in the canine ACL. J Orthop Res 2006; 4: 820-830.
• 9 Chang KV, Hung CY, Aliwarga F. et al. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis archives of physical medicine and rehabilitation. Arch Phys Med Rehabil 2014; 95: 562-575.
• 10 Carmona JU, Arguelles D, Climent F. et al. Autologous platelet concentrates as a treatment of horses with osteoarthritis: a preliminary pilot clinical study. J Equine Vet Sci 2007; 27: 167-170.
• 11 Silva R, Carmona J, Rezende C. Intra-articular injections of autologous platelet concentrates in dogs with surgical reparation of cranial cruciate ligament rupture: a pilot study. Vet Comp Orthop Traumatol 2013; 26: 285-290.
• 12 Schmidt MB, Chen EH, Lynch SE. A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair. Osteoarthritis Cartilage 2006; 14: 403-412.
• 13 Nomura S. Function and clinical significance of platelet-derived microparticles. Int J Hematol 2001; 74: 397-404.
• 14 McCarrel TM, Mall NA, Lee AS. et al. Considerations for the use of platelet-rich plasma in orthopedics. Sports Med 2014; 44: 1025-1036.
• 15 Schnabel LV, Mohammed HO, Miller BJ. et al. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. J Orthop Res 2007; 25: 230-240.
• 16 Catalfamo J, Dodds WJ. Isolation of platelets from laboratory animals. Methods Enzymol 1989; 169: 27-34.
• 17 Baudreaux MK, Ebbe S. Comparison of platelet number, mean platelet volume, and platelet mass in five mammalian species. Comparative Haematology International 1998; 8: 16-20.
• 18 Stief M, Gottschalk K, Ionita J. et al. Concentration of platelets and growth factors in canine autologous conditioned plasma. Vet Comp Orthop Traumatol 2011; 24: 122-125.
• 19 Garcia-Pereira BL, Scott M, Koenigshof AM. et al. Effect of venipuncture quality on thromboelastography. J Vet Emerg Crit Care (San Antonio) 2012; 22: 225-229.
• 20 Rinder HM, Snyder EL, Bonan JL. et al. Activation in stored platelet concentrates: correlation between membrane expression of P-selectin, glycoprotein IIb/IIIa, and beta-thromboglobulin release. Transfusion 1993; 33: 25-29.
• 21 Ault KA. The clinical utility of flow cytometry in the study of platelets. Semin Hematol 2001; 38: 160-168.
• 22 Metcalfe P, Williamson LM, Reutelingsperger CPM. et al. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haemotol 1997; 98: 86-95.
• 23 Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000; 102: 1931-1936.
• 24 Brooks MB, Randolph J, Warner K. et al. Evaluation of platelet function screening tests to detect platelet procoagulant deficiency in dogs with Scott syndrome. Vet Clin Pathol 2009; 38: 306-315.
• 25 Fontenot RL, Sink CA, Were SR. et al. Simple tube centrifugation for processing platelet-rich plasma in the horse. Can Vet J 2012; 53: 1266-1272.
• 26 Dugrillon A, Eichler H, Kern S. et al. Autologous concentrated platelet rich plasma (cPRP) for local application in bone regeneration. Int J Oral Maxillofac Surg 2002; 31: 615-619.
• 27 Italiano JE, Battinelli EM. Selective sorting of alpha-granule proteins. J Thromb Haemost 2009; 7 Suppl. 1 173-176.
• 28 Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med 2011; 39: 2135-2140.
• 29 Zimmermann R, Arnold D, Strasser E. et al. Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates. Vox Sanguinis 2003; 85: 283-289.
• 30 McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am 2012; 94: 143.
• 31 Boswell S, Cole B, Sundman E. et al. Platelet rich plasma: a milieu of bioactive factors. Arthroscopy 2012; 28: 429-439.
• 32 Filardo G, Kon E, Pereira Ruiz MT. et al. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc 2011; 20: 2082-2091.